COVID-19 et maladies auto-immunes dans un centre de traitement des épidémies à Dakar
Résumé
Texte intégral :
PDFRéférences
World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard 2021.2. Richez C. Sévérité de l’infection COVID-19 chez les patients atteints de maladies inflammatoires : résultats de la cohorte « French RMD COVID-19 » Rev Rhum 2020 ; 87 (1) : A1-A3083. Williamson, E. J. et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020 ; 584 : 430-4364. Akiyama S, Hamdeh S, Micic D et al. Prevalence and Clinical Outcomes of COVID-19 in Patients With Autoimmune Diseases: A Systematic Review and MetaAnalysis. Ann Rheum Dis 2020; 80 (3): 2189465. Meyer A, Chateluis E, Pijnenburg L, Poindron V, Guffroy A et al. Prévalence du COVID-19 et des poussées inflammatoires chez les patients atteints de maladie auto-immunes systémiques rares : enquête systématique téléphonique et sérologique dans un centre national de référence. Rev Rhum 2020 ; 87 : A2896. Abbassi IM, Aydil Z, Rachdi I, Somaï M, Ben Dhaou B, Daoud F, Boussema F. Maladies systémiques et infections par la Covid-19 : étude d’une série de 50 patients. Rev Med Int 2021 ; 42 : A347-A4527. Gianfrancesco MA, Hyrich KL, Gossec L, et al. Rheumatic Disease and COVID-19: Initial Data from the COVID-19 Global Rheumatology Alliance Provider Registries. Lancet Rheumatol 2020; 2: e250-38. Ramirez GA, Moroni L, Della-Torre E et al. Systemic Lupus Erythematosus and COVID-19: What We Know so Far. Ann Rheum Dis 2020; 79: 2186019. Liu Yu, Sawalha Amr H, Lu Qianjin. COVID-19 et maladies auto-immunes. CURRENT OPINION IN RHUMATOLOGY 2021; 33 (2): 155-16210. Danza A, Ruiz-Irastorza G. Infection Risk in Systemic Lupus Erythematosus Patients: Susceptibility Factors and Preventive Strategies. Lupus 2013; 22: 1286-94 11. Sawalha AH, Zhao M, Coit P, et al. Epigenetic Dysregulation of ACE2 and Interferon-Regulated Genes Might Suggest Increased COVID-19 Susceptibility and Severity in Lupus Patients. Clin Immunol 2020; 215: 10841011. Lu C, Li S, Liu Y. (2020) Role of immunosuppressive therapy in rheumatic diseases concurrent with covid-19. Ann Rheum Dis: annrheumdis-2020-217460 12. Verdon A, Zanisi L, Pianta C.M, Ludici M. Lupus érythémateux systémique et COVID-19. Rev Med Suisse 2021 ; 17 : 487-9013. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 ; 30 (3): 269-71
Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020; 6: 1615. Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG. et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005; 2: 6916. Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today’s diseases? Lancet Infect Dis. 2003 ; 3 (11): 722-717. Horisberger A, Moi L, Ribi C, Comte D. Maladies auto-immunes dans le contexte de la pandémie COVID-19. Rev Med Suisse 2020 ; 16 : 827-3018. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX et al. China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382: 1708-172019. Fredi M, Cavazzana I, Moschetti L et al. COVID-19 in Patients With Rheumatic Diseases in Northern Italy: A singleCentre Observational and Case-Control Study. Lancet Rheumatol 2020; 2: e549-56 20. FAI2R/SFR/SNFMI/SOFREMIP/CRI/IMIDIATE Consortium and Contributors. Severity of COVID-19 and Survival in Patients With Rheumatic and Inflammatory Diseases: Data from the French RMD COVID-19 Cohort of 694 Patients. Ann Rheum Dis 2020; 80 (4): 527-538 21. Wang Q et al. Risk and clinical outcomes of Covid-19 in patients with rheumatic diseases compared with general population: systematic review and metaanalysis. Rheumol Int 2021. 41 (5): 851-86122. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020 ; 368: m1091
Renvois
- Il n'y a présentement aucun renvoi.